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ABSTRACT  
In the pharmaceutical field controlled release products have the ability to maintain desired medicament concentration or a longer period of 
time. Certain drugs are relatively insoluble in water and have high dose requirements that render unsuitable formulation difficulties in 
sustained release formulations. Nitazoxanide which is a high dose water insoluble antiprotozoal drug was formulated with the aim. To 
modulate gastro-retentive dosage form based on the superporous hydrogel composites. Foaming technique was used in the preparation of SPH 
composites. The superporous hydrogels were extremely sensitive to pH of swelling media and good porosity. Superporous hydroge ls tablets of 
nitazoxanide showed good pre-compressional and post-compressional properties. Formulation X is the best formulation containing chitosan, 
polyvinyl alcohol, formaldehyde, exhibited good swelling ratio. The compatibility studies were performed by Fourier Transform Infrared (FT-
IR) Spectroscopic Studies, Differential Scanning Calorimetry Studies (DSC). All formulations were evaluated for stability, drug content, and 
kinetic drug release & in-vitro drug release profile. It was concluded that the proposed gastro-retention drug delivery provides a different 
supply of nitazoxanide directly to the stomach. 
Keywords: Nitazoxanide, Anti protozoal, foaming technique, Chitosan 
 
Article Info: Received 21 March 2020;     Review Completed 28 April 2020;     Accepted 11 May 2020;     Available online 15 June 2020 
Cite this article as: 
Srikala SV, Santhi Priya N, Nadendla RR, Formulation, Characterization and Antihelminthic Activity Testing of 
Nitazoxanide Superporous Hydrogel Tablets, Journal of Drug Delivery and Therapeutics. 2020; 10(3-s):26-36 
http://dx.doi.org/10.22270/jddt.v10i3-s.4130                                                                                                      
*Address for Correspondence:  
Nagam Santhi Priya, Assistant professor, Department of pharmaceutics, Chalapathi institute of pharmaceutical sciences, Lam, G untur, Andhra 
Pradesh, India 
 
 
INTRODUCTION 
Hydrogels are hydrophilic, cross linked polymers which are 
able to absorb large amounts of water and remain water in 
soluble all though slow swelling is beneficial their arises 
situations where a fast swelling polymer is more desirable 
therefore a new generation of hydrogels1. Which swell and 
absorb water rapidly has been developed and is termed as 
superporous hydrogels which swell to an extent of uniform 
and equilibrium size in a short span of time. The synthesis 
involves either cross linking of monomers using 
multifunctional cross linking agent usually by 
polymerization and gas blowing technique or 
copolymerization by using chemical compounds/ 
irradiation2. For drug delivery applications conventional 
hydrogels is limited due to slow swelling kinetics. 
Improvement of swelling rate is possible by making 
hydrogel porous or superporous. The word superporous 
means the pore structure of the hydrogel is open and 
connected. In this way the water will be absorbed into the 
hydrogel structure by means of diffusion and capillary 
actions. The draw back here is the more porous the structure 
is the weaker the hydrogel structure so to improve 
mechanical properties foaming and gelation process are 
used to improve compressive strength, elasticity3.  
Nitazoxanide is an antihelminthic and antiprotozoal agent 
having broad spectrum of activity. It is chemically 2-
acetyloxy (N-(5-nitro-2thiazolyl) benzamide. Nitazoxanide is 
a light yellow crystalline powder which is insoluble in water 
and poorly soluble in ethanol. It belongs to BCS class II drug 
in biopharmaceutical classification system i.e. low solubility 
and high permeability. It is used for treating diarrhea caused 
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by Giardia lambila as well as for cryptosporidiosis in 
immune-compromised patient4. 
The pharmaceutical composition of tablet dosage form 
comprises of a first portion of nitazoxanide in a controlled 
release manner and second portion with second quantity of 
nitazoxanide for immediate release effect here the control 
release property is assumed where in absorption and 
bioavailability of the active agent over extended period of 
time and also the immediate release portion of the active 
agent is made bio available without substantial delay. In the 
present research work 23 full factorial design i.e. 3 factors 
and 2 levels was used to optimize the concentrations of 
chitosan, polyvinyl alcohol, microcrystalline cellulose and 
response is cumulative % drug release by using Design-
Expert software. 
MATERIALS AND METHODS 
Materials 
Chitosan, Poly vinyl alcohol (PVA), Formaldehyde and 
Sodium bicarbonate, microcrystalline cellulose, 
magnesium stearate, talc were obtained by Chalapathi 
institute of pharmaceutical sciences, lam, Guntur.  
Nitazoxanide is a kind gift sample from pellets pharma 
limited. 
Methods 
Preparation of nitazoxanide loaded Superporous 
Hydrogels 
Chitosan is dissolved in 0.1M acetic acid solution to obtain 
2%w/v. A 10%w/v aqueous solution of PVA was prepared. 
The chitosan solution was dispersed in PVA solution and 
homogenized for 15 minutes definite composition of 
formaldehyde was added as crosslinking agent. Calculated 
quantities of sodium bicarbonate was added and 
homogenized for a period of 4hours in ultraterax to induce 
uniform gelation, crosslinking and effervescent reactions. 
The swelled and formed hydrogels were left to stand 
overnight at room temperature. The hydrogels were freeze 
dried for 12 hours. The freeze dried samples were stored in 
well closed container. (Table no.1) 
Formulation of SPH tablets of nitazoxanide 
500mg drug equivalent superporous hydrogel, 
microcrystalline cellulose were weighed accurately were 
taken in a poly bag and blended by shaking for 10 minutes. 
To the powder blend magnesium stearate, talc, sodium 
bicarbonate were added and were mixed for 5 more minutes 
by shaking to ensure complete mixing. The powder blend is 
passed through 80 sieve and were compressed into tablets. 
(Table no.2) 
Anthelmintic activity in Pheretima posthuma  
Collection of Pheretima posthuma: Pheretima posthuma 
were collected from the swampy water along with 
amaravathi road, Chalapathi institute of Pharmaceutical 
Sciences, lam, Guntur, Andhra Pradesh, India. The average 
size of worms was 5-9cm. 
Preparation of drug solutions: The standard drug 
metronidazole was received from chalapathi institute of 
pharmaceutical sciences and test samples were synthesized 
in chalapathi drug testing laboratory, chalapathi institute of 
pharmaceutical sciences. Metronidazole and test samples 
were prepared as Group-I is contains saline (0.9% Nacl in 
water), Group-II is containing metronidazole as a reference 
standard (400mg/ml), Group-III containing NSPH-I 
(nitazoxanide loaded superporous hydrogel) (200mg/ml), 
Group-IV containing NSPH-II (400mg/ml). 
Optimization by 23 Factorial Designs 
The 23  full factorial designs were carried out systematically 
with 3 factors at 2 levels to prepare the nitazoxanide loaded 
SPH tablets. A total of 8 experimental trials were done at all 
possible combinations. During optimization of excipient the 
amount of chitosan, Polyvinyl alcohol, Microcrystalline 
cellulose and response is cumulative % drug release were 
selected as the independent variables that were varied at 2 
levels i.e. low and high. (Table 3) 
RESULTS AND DISCUSSIONS 
Characterization of superporous hydrogels 
The following parameters are suitable for superporous 
hydrogels 
Physical Appearance: Clarity, color, and presence of any 
particles were examined visually in the prepared hydrogels. 
Percent Yield of SPH: The percent yield represents the 
amount of material produced after SPH freezing, compared 
with the amount retained for freeze drying. The formula can 
be calculated by, 
                 
                              
                              
     
Drug content of SPH: Superporous hydrogel drug content 
was calculated to assess how much of a particular amount of 
superporous hydrogel is present. We taken in 100 ml 
volumetric flask, a superporous hydrogel required was 
taken. After that 10ml of buffer was added, mixed well and 
make upto volume. The above mixture was filtered, and drug 
content determined by using correct wavelength of a UV 
visible spectrophotometer 5. 
Gelatin Kinetics:  The reaction to polymerization continues 
to increase the viscosity until the whole structure of the 
network gel is formed. Gelation time was calculated as the 
gel forming period and measured with a simple method of 
tilting with acetic acid after pH adjustment to 5.0. This 
parameter was taken as the time required for the reactant to 
avoid falling into the tilted tube position6. 
Swelling Studies: Swelling studies included swelling time 
and swelling ratio. 
Swelling Time: Swelling time is time taken by the hydrogel 
to reach its equilibrium swelling point where swelling is 
prevented. Swelling is usually measured gravimetrically and 
volumetrically a texture analyzer is used to assess swelling 
time. Dried SPH was allowed to hydrate more than swelling 
medium (25ml) at room temperature. At various time 
periods, the hydrogel was separated from the solution and 
measured after excess solvent on the surface was blotted. 
 Swelling Ratio: The swelling behavior of prepared SPH was 
carried out by the ‘T’ bag weight method in which 0.1g of 
sample was added to a small bag made of nylon 
(50mm×90mm) 200mesh. The bag was completely 
immersed in the swelling media (200ml) simulated gastric 
fluid pH 1.2 at room temperature for 24 hrs to each the 
swelling equilibrium. Adhered liquid droplets on the surface 
of samples were removed by blotting with tissue paper. The 
swollen SPH & then dried in oven at 60ºC for 6hrs until there 
was a no change in the weight of samples the equilibrium 
swelling was defined as follows. (Figure 1) 
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Where, Ws is the weight of the swollen superporous 
hydrogel, Wd is the weight of the dried superporous hydrogel 
and Qs is equilibrium swelling ratio7. 
Density Measurement: Dried SPHC was used for density 
measurements, which actually showed an apparent density 
of SPHC. A sample of SPHC was taken and weighed to 
evaluate the mass of the piece. A sample of the polymer was 
dipped into a predetermined volume of hexane in a 
graduated cylinder and the rise in hexane volume was 
measured as the volume of the polymer. Density was 
calculated by  
        
     
     
                 
Where, VSPHC is the volume of the solvent displaced by SPHC, 
MSPHC is the mass of the SPHC 8 
Porosity Measurement: The solvent replacement process 
has been used for porosity measurement. The dried 
hydrogels were absorbed overnight in absolute ethanol and 
weighed after unwanted ethanol on the surface was blotted. 
The porosity of the following equation was calculated. 
         
     
  
               
Where, M1 and M2 are the mass of the hydrogel before and 
after absorbed in absolute ethanol, ρ is the density of 
absolute ethanol and V is the volume of the hydrogel9.  
Measurement of Void Fraction: By immersion of the 
hydrogels into HCl (pH 1.2) buffer upto equilibrium swelling, 
the void fraction was identified inside superporous 
hydrogels. The dimensions of the swollen hydrogels were 
measured and the sample volumes were determined as 
dimensional volumes by using these data. Meanwhile, the 
amount of buffer absorbed in the hydrogels was determined 
by removing the weight of the dry hydrogel from the weight 
of the hydrogel swollen, the resulting values were assigned 
as the total volume of pores in the hydrogels.  Void fraction 
calculated by following formula 10 (Table 4) 
              
                                  
                     
              
Water Retention: Water retention capacity (Wrt) as a 
function of time at 37oC, was used to determine the 
following formula. 
    
     
     
    
Where, Wd is the weight of dried hydrogel, Ws is the weight 
of fully swollen hydrogel and Wp is weights of the hydrogel 
at various exposure times 11. (Table 5) 
Characterization of tablets 
The formulated tablets were evaluated for following 
parameters 
Pre Compressional Parameter: 
Angle of Repose: The angle of repose of the granules was 
determined by using the funnel method suggested by 
Neumann. The accurately weighed granules were taken in a 
funnel. The funnel height was raised to the point of the top of 
the granule heap. This funnel height was changed. The 
granules were allowed to flow freely to the surface through 
the funnel. The powder cone diameter has been determined, 
and the angle of repose was calculated by using the 
following formula, 
         ⁄   
Bulk Density: Bulk density is the ratio of mass and bulk 
volume. Accurately weighed 20 g granules were allowed to 
flow in a fine stream into a graduated cylinder and final 
volume was noted.  
             
        
           
 
Tapped Density: The 20gm blend into a graduated cylinder 
of a mechanical tapping instrument was permitted in the 
fine stream. The measuring cylinder was tapped for 100 
times, and final tapped volume was measured. Tapped 
density formula was calculated by, 
               
        
             
 
Carr’s Index: Carr’s index evaluates interparticulate 
cohesive characteristics with the angle of repose 
measurements and studies the effects of bulk- tapped solid 
packing geometry. 
             
                           
            
     
Hausner’s Ratio: Hausner’s ratio is a simple method to 
evaluate the stability of the powder column and to estimate 
flow properties. Hausner’s ratio was calculated using 
formula. (Table 6)  
                
              
            
      
Post Compressional Parameter: 
Tablet thickness: Thickness and diameter of tablets were 
important for uniformity of tablet size. Thickness and 
diameter were measured using Vernier caliper. 
Hardness: The hardness test was calculated by taking 6 
tablets of every formulation and adding the strength to the 
tablet by using Monsanto hardness tester. 
Friability:  Friability test was performed by using Roche 
friabilator. The 20 tablets were weighed separately and 
placed in the drum that revolves at 25 r/min dropping the 
tablets through a distance of six inches with each revolution. 
After 4 min the tablets were weighed, and the percentage 
loss in tablet weight was calculated by using formula,  
      
     
  
     
Where, W0 is the initial weight of tablets and Wf  is finals 
weight of tablets. 
Weight uniformity: 20 tablets were previously punched 
and measured there on a digital weighing balance. After that 
each tablet were weighed. The weight of a tablet was 
determined by our collective weight   
Content of Uniformity: 
The drug content is considered to check dose uniformity in 
the formulation. Total 20 tablets were weighed and 
powdered. The stock solution was prepared by dissolving a 
drug powder equivalent to 10 mg in 10 ml water. The stock 
solution was shaken on a sonicator for 20 minutes. 
This resultant solution was further diluted with water to 
attain concentration upto 10µg/ml and the absorbance was 
measured at 286nm. (Table 7). 
In-vitro Dissolution Study: 
The in-vitro dissolution study was performed by using USP 
apparatus type II at 37oC ± 0.5oC using 900ml hydrochloric 
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acid buffer (pH-1.2) as a dissolution medium at 50 r/min. 
5ml samples were withdrawn and replaced by new 
dissolution media at predetermined time intervals. The 
dissolution was continued the apparatus was allowed to the 
12hours the graphs of time vs percentage release were 
plotted. Withdrawn samples was filtered through a 0.45µm 
membrane filter, diluted and assayed at 286nm using a UV-
VIS spectrophotometer. Cumulative percentage drug release 
was calculated by using an equation obtained from a 
calibration curve. To ascertain the order and mechanism of 
drug release the in-vitro release data was subjected to 
various kinetic equations. 
Kinetic Models  
Treatment of dissolution data with different kinetic 
equations: 
 In order to consider the mechanism of release and release 
rate kinetics of the dosage form, the data attain were fitted 
into Zero order, First order, Higuchi matrix, and Korsmeyer 
and Peppas. Based on the r-value, the best-fit model selected. 
Zero Order Kinetics: 
Zero-order release would be concluded by the given 
formula: 
  
  
    
Where, Q = Drug released at time‘t’ 
K0 = Zero-order rate constant (h-1). 
When the data is plotted as cumulative percent drug 
released vs time, if the plot is linear then the data obeys 
zero-order release kinetics, with a slope equal to K0. 
First Order Kinetics:  
To study the first order release rate kinetics, the release rate 
data were fitted to the given formula: 
  
  
     
Where, Q = Amount of drug remained at time‘t’ 
K1 = First-order rate constant (h-1). 
When the data is plotted as log cumulative percent drug 
remaining versus time; yields a straight line, indicating that 
the release follows first-order kinetics. The constant ‘K1’ can 
be obtained by multiplying 2.303 with slope values. 
Higuchi model: 
Higuchi developed several hypothetical models to study the 
release of water soluble and low soluble drugs incorporated 
in semisolids and/or solid matrices. Mathematical 
expressions were obtained for drug particles dispersed in a 
uniform matrix behaving as the diffusion media. And the 
given equation is, 
           
Where, Qt = amount of drug released in time t, 
KH = Higuchi dissolution constant 
Korsmeyer and Peppas model: 
The release rate from sustained release polymeric matrices 
can be described by the equation proposed by korsmeyer et 
al. 
        
Where, Q = amount of drug released at time‘t’ 
KKP = Kinetic constant incorporating structural and 
geometric characteristics of the tablets 
‘n’ = The diffusional exponent, indicative of the release 
mechanism. 
The release exponent, n, is the slope of log fraction of drug 
release vs log time cure. (Table 8) (Figure 2) 
Stability Studies:  
Stability studies on promising formulation were carried out 
in compliance with ICH guidelines by storing tablets at 40oC 
/75% relative humidity for 3 months. 
The sample was withdrawn at fixed time intervals of 0 
(initial), 30, 60 and 90 days. At the end of three months, the 
time interval the tablets were tested for any hardness, 
changes in drug content, physical changes, and in-vitro 
dissolution studies. (Table 9) (figure 3). 
Compatibility Studies: 
Fourier Transform Infrared (FT-IR) Spectroscopic 
Studies 
The compatibility between the pure nitazoxanide and SPH & 
combination of nitazoxanide + PVA and pure PVA was tested 
by using FT-IR spectroscopy. The chemical structure of the 
synthesized hydrogels was also studied. The FTIR spectrum 
was recorded and the range of 400-4000cm-1 using KBr 
pellet method. (Figure 4) 
Differential Scanning Calorimetry Studies (DSC) 
The DSC was carried out for pure drug, tablet using a 
SHIMADZU DSC-60 plus differential scanning calorimeter. 
The system was calibrated with a high purity sample of 
nitazoxanide. Sample was scanned at the heating rate of 
10°C/min over a temperature range of 50 to 250°C under 
nitrogen gas using aluminum pans. (Figure 5) 
Evaluation of Anthelmintic activity using Pheretima 
posthuma: Take 12 petridishes containing 10ml of sample 
in each petridish. Four groups were taken.  
In group-I three petridishes were taken. In each petridish 
10ml of saline solution was poured and one Pheretima 
posthuma was placed. 
In group-II three petridishes were taken. In each petridish 
10ml of metronidazole as a standard solution was poured 
and one Pheretima posthuma was placed. 
In group-III three petridishes were taken. In each petridish 
10ml of NSPH-I (nitazoxanide loaded superporous hydrogel) 
solution was poured and one Pheretima posthuma was 
placed. 
In group IV three petridishes were taken. In each petridish 
10ml of NSPH-II solution was poured and one Pheretima 
posthuma was placed. Observations were recored for (Table 
10) the time taken for paralysis and time taken for death in 
minute. (Figure 6)  
Optimized 23 Factorial design 
To classify the most important factors among all the factors, 
selection is done at beginning of the experimental 
procedure. From the experimental results, the effects of all 
studied variables and the variable interactions were 
graphically and statistically interpreted for all responses. 
The optimized nitazoxanide loaded SPH was used for the 
preparation of tablets. (Table 11) 
The application of factorial design yielded the following 
regression equation. 
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Cumulative % drug release =  
-113.50333+99.20833×Chitosan+38.75000×PVA+1254.5000×MCC. 
Where, negative values indicate a negative effect of a specific 
variable on the response factor and positive value indicates 
positive effect of a specific variable. The polynomial 
regression result was expressed using 3D graph and contour 
plot. (Figure 7) 
The ANOVA studies indicated that all models were 
significant (p<0.05) for all response parameters scrutinized. 
Model simplification was done by removing non-significant 
terms (p>0.05) in polynomial equations. (table.12)
 
Table 1: Formulation of Superporous Hydrogels 
 
Ingredients (mg) 
Formulation 
I II III IV V VI VII VIII IX X 
Chitosan (2% W/V) 40 80 120 160 80 80 80 80 80 80 
Polyvinyl alcohol (10% W/V) 400 400 400 400 200 200 400 400 400 800 
Formaldehyde (10% V/V) 400 400 400 400 400 400 400 200 600 800 
Sodium bicarbonate 80 80 80 80 80 80 80 80 80 80 
Nitazoxanide 500 500 500 500 500 500 500 500 500 500 
 
Table 2: Formulation of SPH tablets of Nitazoxanide 
 
Ingredients (mg) 
Formulation 
I II III IV V VI VII VIII IX X 
Nitazoxanide 500 500 500 500 500 500 500 500 500 500 
Microcrystalline 
cellulose 
61.32 72.83 81.7 65.17 49.39 52.27 69.59 49.59 58.5 86.7 
Sodium bicarbonate 16 16 16 16 16 16 16 16 16 16 
Magnesium stearate 4 4 4 4 4 4 4 4 4 4 
Talc 2 2 2 2 2 2 2 2 2 2 
 
Table 3: Variables in 23 Factorial Design 
Independent Variable Levels 
Low High 
A: Chitosan 0.04% 0.16% 
B: PVA 0.2% 0.8% 
C: MCC 0.09% 0.12% 
Dependent Variable 
Cumulative % drug release 
 
Table 4: Characterization of superporous hydrogels 
Batch 
code 
Parameters 
Percent 
Yield (%) 
Drug 
content (%) 
Gelation 
time (sec) 
Swelling 
time (min) 
Swelling 
ratio 
Density 
(g/cc) 
Porosity 
(%) 
Void 
fraction 
(%) 
1 20.45±0.11 84.54±0.01 31.22±0.54 5.01±0.02 103.33±5.15 0.49±0.02 3.65±0.22 5.75±1.88 
2 18.23±0.15 95.46±0.56 35.12±0.86 5.00±0.01 120.25±2.98 0.51±0.03 5.20±0.16 4.01±0.31 
3 15.46±0.42 104.80±0.01 29.56±0.01 5.12±0.03 140.20±2.88 0.23±0.01 8.25±0.30 3.77±0.20 
4 12.33±0.20 108.45±0.01 14.52±0.54 5.19±0.01 182.66±7.98 0.26±0.01 9.23±0.23 3.45±0.35 
5 21.50±0.21 75.48±0.20 22.10±1.02 5.02±0.01 118.66±4.98 0.49±0.00 18.25±0.25 3.75±0.38 
6 14.28±0.19 80.75±0.25 20.16±0.89 4.56±0.04 105.45±0.06 0.35±0.00 30.24±3.02 2.75±0.25 
7 13.20±0.43 90.20±0.01 16.45±1.35 5.00±0.00 55.44±5.12 0.30±0.02 29.13±0.05 1.99±0.15 
8 10.25±0.30 76.25±0.01 80.66±1.25 4.88±0.19 83.65±5.02 0.25±0.00 24.52±0.02 2.58±0.14 
9 15.55±0.56 85.13±0.01 91.00±0.01 5.09±0.15 25.55±2.22 0.30±0.02 3412±4.44 1.45±0.02 
10 25.79±0.33 89.51±0.01 192.22±2.5 5.00±0.01 20.00±5.20 0.35±0.01 40.11±0.20 1.89±0.14 
 
Srikala et al                                                                                                             Journal of Drug Delivery & Therapeutics. 2020; 10(3-s):26-36 
ISSN: 2250-1177                                                                                  [31]                                                                                 CODEN (USA): JDDTAO 
Table 5: Water Retention capacity 
S.NO. Time Water retention capacity 
1 0 0.9 
2 3 0.75 
3 6 0.82 
4 9 0.85 
5 12 0.92 
6 15 0.87 
7 18 0.84 
8 21 0.87 
9 24 0.84 
 
Table 6: Precompressional parameters of SPH tablets 
Batch 
code 
Precompressional parameters 
Bulk density 
(g/cm3) 
Tapped density (g/cm3) Carr’s index 
(%) 
Hauner’s ratio Angle of 
repose(o) 
1 0.23±0.0012 0.25±0.0080 8.00±0.26 1.08±0.032 22.30±1.22 
2 0.25±0.0093 0.30±0.00 16.66±2.25 1.2±0.035 26.40±5.24 
3 0.26±0.0075 029±0.016 10.34±4.55 1.11±0.06 30.20±1.20 
4 0.18±0.0042 0.25±0.042 25.00±2.24 1.38±0.05 28.31±1.60 
5 0.59±0.014 0.80±0.089 26.25±6.25 1.35±0.08 20.15±3.25 
6 0.48±0.026 0.59±0.040 18.64±8.45 1.22±0.10 19.00±1.25 
7 0.45±0.021 0.50±0.58 10.02±0.32 1.11±0.05 22.14±2.20 
8 0.40±0.020 0.45±0.25 11.11±7.45 1.12±0.04 30.25±1.46 
9 0.20±0.001 0.23±0.0035 13.05±1.26 1.15±0.02 18.42±1.25 
10 0.30±0.00 0.35±0.015 14.28±2.05 1.16±0.05 25.21±1.41 
 
Table 7: Post compressional parameters of SPH tablets 
Batch 
code 
Post Compressional parameters 
Weight 
variation (%) 
Diameter 
(mm) 
Thickness 
(mm) 
Hardness 
(g/cm2) 
Friability 
(%) 
Disintegration 
time (min) 
Content 
uniformity 
1 0.25±0.246 7.08±0.005 2.75±0.000 4.45±0.055 0.224 28.44±1.51 98.58±0.85 
2 0.22±0.244 7.05±0.004 2.74±0.001 4.44±0.052 0.122 29.22±1.51 98.52±0.55 
3 0.19±0.22 7.05±0.003 2.74±0.003 4.40±0.051 0.225 36.00±1.00 99.71±083 
4 0.23±0.210 7.08±0.000 2.74±0.000 4.42±0.050 0.250 30.00±0.55 99.99±0.25 
5 0.25±0.21 7.04±0.001 2.74±0.005 4.45±0.053 0.228 40.12±0.57 100.0±0.74 
6 0.26±0.19 7.04±0.005 2.74±0.004 4.40±0.056 0.200 27.66±0.57 99.97±0.50 
7 0.27±0.20 7.05±0.000 2.74±0.000 4.44±0.053 0.220 35.22±0.55 98.98±0.85 
8 0.18±0.23 7.04±0.002 2.74±0.001 4.43±0.054 0.224 33.25±0.54 97.58±0.88 
9 0.25±0.21 7.05±0.005 2.74±0.002 4.40±0.051 0.222 31.55±1.24 99.58±0.77 
10 0.24±0.26 7.05±0.000 2.74±0.000 4.41±0.050 0.244 34.25±0.45 100.1±0.64 
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Table 8: Drug release kinetics of optimized formulations 
Batch no F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 
Model 
name 
R2 R2 R2 R2 R2 R2 R2 R2 R2 R2 
Zero Order 0.7599 0.7044 0.8541 0.7872 0.776 0.8361 0.8377 0.8391 0.8189 0.8083 
First Order 0.784 0.7296 0.8734 0.8185 0.8081 0.8657 0.8696 0.87 0.8523 0.8422 
Higuchi 
mode 
0.9289 0.8971 0.9254 0.9369 0.9255 0.9505 0.9685 0.9541 0.9628 0.9548 
Kor’s 
peppas 
0.4759 0.4206 0.4944 0.4702 0.4477 0.5081 0.5499 0.5175 0.5315 0.512 
 
Table 9: Drug content data of stability studies 
Time 90days 60days 30days 0days 
10000 89.26 89.3 89.43 89.72 
20000 90 90.02 90.05 90.08 
30000 94.16 94.27 94.38 94.48 
40000 93.05 93.17 93.21 93.29 
50000 97.81 97.88 98 98.03 
60000 93.66 93.75 93.86 93.97 
70000 95.55 95.65 95.79 95.87 
80000 94.14 94.26 94.38 94.49 
90000 98.33 98.42 98.53 98.66 
100000 99.24 99.32 99.41 99.52 
 
Table 10:  Antihelminthic activity of Nitazoxanide loaded SPH 
Name of the 
group 
Treatment group Sample 
concentration 
Time taken for paralysis 
in minutes 
Time taken for death 
in minutes 
Group –I Vehicle (Saline) 0.9% Nacl - - 
Group –II Metronidazole 400mg/ml 30 45 
Group –III NSPH –I 200mg/ml 75 80 
Group –IV NSPH –II 400mg/ml 55 66 
 
Table 11: Observed response in 23 factorial design for formulation f10 
Std. Run Factor 1 Factor 2 Factor 3 Response 
A:Chitosan B:PVA C:MCC Cumulative % drug release 
6 1 0.16 0.2 0.12 54.14 
3 2 0.04 0.8 0.09 29.51 
7 3 0.04 0.8 0.12 74.67 
1 4 0.04 0.2 0.09 25.07 
4 5 0.16 0.8 0.09 32.86 
2 6 0.16 0.2 0.09 27.35 
5 7 0.04 0.2 0.12 37.00 
8 8 0.16 0.8 0.12 99.52 
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Table 12: ANOVA for selected factorial model response of % cumulative drug release 
Source Sum of Squares df Mean square F-value P-value 
Model 4197.37 3 1399.12 6.60 0.0499 
A-chitosan 283.4 1 283.46 1.34 0.3120 
B-PVA 1081.12 1 1081.12 5.10 0.0869 
C-MCC 2832.79 1 2832.79 13.36 0.0217 
Residual 848.35 4 212.09   
 
 
 
Figure 1: (a) Before swelling, (b) After swelling 
 
 
Figure 2: Drug release kinetic models for (a) zero order (b) first order (c) higuchi plot (d) kors-peppas 
 
 
(b
) 
(a) 
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Figure 3: Dissolution profile of stability studies 
 
 
Figure 4: Comparison of FTIR study of nitazoxanide (a) Pure nitazoxanide and SPH, 
 
 
 
 
 
 
 
(a) 
(b) 
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Figure 5: DSC graphs for (a) nitazoxanide loaded SPH tablet (b) Pure Nitazoxanide 
 
Figure 6: Antihelminthic activity-time of paralysis testing of SPH tablets in Pheretima posthuma 
 
Figure 7: DOE Plots for (a) 3D Surface plot (b) Contour plot 
(a) 
(b) 
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CONCLUSION 
This study discusses the preparation of nitazoxanide loaded 
superporous hydrogel tablets. The superporous hydrogel 
tablets of nitazoxanide were prepared by direct compression 
method. This study is mainly based on chitosan and used as a 
carrier. The SPH tablets of nitazoxanide showed good pre-
compressional, post-compressional properties and better in-
vitro drug release profiles are showed in this work. FI-IR and 
DSC studies showed that the drug was compatible with SPHC 
particles. The formulation F10 prepared by direct 
compression containing SPH tablets of nitazoxanide were 
optimized by using 23 factorial design and prepared by cross 
linking technique exhibited good swelling index as well as 
maximum rate of drug release. So, finally all formulations were 
successfully formulated. This study also demonstrates that 
superporous hydrogel tablets may be suitable for use as a 
gastro-retentive drug delivery system. 
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